Key result
Young-onset AF is linked to a ~28% MACCE rate, with LGE predicting risk.
Why the study?
The long-term prognosis and etiology of atrial fibrillation in young individuals with preserved ejection fraction are poorly understood.
What are the prevalence and predictors of adverse outcomes in young individuals (≤45 years) with atrial fibrillation and normal left ventricular function?
Cohort (n=203)
Yes
What are the prevalence and predictors of adverse outcomes in young individuals (≤45 years) with atrial fibrillation and normal left ventricular function?
Answers are grounded in this paper and cite their sources.
Young-onset atrial fibrillation is associated with a significant rate of adverse events, with genetic/structural etiologies and late gadolinium enhancement identifying patients at particularly high risk.
BACKGROUND: Atrial fibrillation (AF) has been traditionally regarded as a disease of aging, although its prevalence in young individuals is now recognized. The long-term prognosis of AF in young individuals, especially in those with preserved ejection fraction, is poorly understood. OBJECTIVES: The goal of this study was to determine the prevalence and predictors of adverse outcomes in a contemporary cohort of young individuals with AF. A further goal was to determine the etiology of early onset AF. METHODS: The YOUNG-AF study is a multicenter retrospective cohort study that included adults diagnosed with a first episode of AF at age ≤45 years with normal left ventricular function and referred for catheter ablation. Major adverse cardiovascular and cerebrovascular events (MACCE) and demographic information were collated. A comparator cohort of 45- to 60-year-old patients, additionally referred for AF ablation, was also collated. RESULTS: Among 203 patients (mean age 34.8 ± 7.7 years; 79% male), mean ejection fraction was 59% ± 5%. During a median follow-up of 4.9 years (Q1-Q3: 2.5-10.2 years), MACCE occurred in 28% of patients, and new left ventricular dysfunction developed in 13% of cases. Genetic, alcohol, or structural heart disease-associated AF etiology was associated with the highest event burden, whereas idiopathic, non-pulmonary vein triggers, exercise, and vagal-associated AF displayed a more favorable prognosis. Catheter ablation was performed in 180 (88.7%) patients. Recurrence was observed in 70 (39%) patients, with a median time to recurrence of 4.3 months (Q1-Q3: 1.5-10.4 months). The presence of late gadolinium enhancement predicted MACCE and shorter recurrence-free survival (P < 0.01). CONCLUSIONS: Young-onset AF was associated with a significant rate of adverse events, with genetic and structural heart abnormalities conferring the worst prognosis. Young patients continue to do well after catheter ablation, although late gadolinium enhancement may identify a group at particularly high risk.
No takes yet. Share an insight, caveat, or question.
D’Elia et al. (2026) conducted a cohort in Atrial fibrillation (n=203). Young-onset atrial fibrillation vs. 45- to 60-year-old patients with atrial fibrillation was evaluated on Major adverse cardiovascular and cerebrovascular events (MACCE). Young-onset atrial fibrillation was associated with a 28% rate of major adverse cardiovascular and cerebrovascular events over 4.9 years, with late gadolinium enhancement predicting risk.
Synapse has enriched 10 related papers. Consider them for comparative context: